BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37567101)

  • 21. DNA Methylation Profiles of Ovarian Clear Cell Carcinoma.
    Cunningham JM; Winham SJ; Wang C; Weiglt B; Fu Z; Armasu SM; McCauley BM; Brand AH; Chiew YE; Elishaev E; Gourley C; Kennedy CJ; Laslavic A; Lester J; Piskorz A; Sekowska M; Brenton JD; Churchman M; DeFazio A; Drapkin R; Elias KM; Huntsman DG; Karlan BY; Köbel M; Konner J; Lawrenson K; Papaemmanuil E; Bolton KL; Modugno F; Goode EL
    Cancer Epidemiol Biomarkers Prev; 2022 Jan; 31(1):132-141. PubMed ID: 34697060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma.
    Sato E; Nakayama K; Razia S; Nakamura K; Ishikawa M; Minamoto T; Ishibashi T; Yamashita H; Iida K; Kyo S
    Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29890703
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma.
    Zhu J; Wen H; Bi R; Wu Y; Wu X
    J Gynecol Oncol; 2017 Nov; 28(6):e77. PubMed ID: 29027395
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical analysis and literature review of a case of ovarian clear cell carcinoma with PIK3CA gene mutation: A case report.
    Farah AM; Gu S; Jia Y
    Medicine (Baltimore); 2022 Sep; 101(37):e30666. PubMed ID: 36123851
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma.
    Kuroda T; Ogiwara H; Sasaki M; Takahashi K; Yoshida H; Kiyokawa T; Sudo K; Tamura K; Kato T; Okamoto A; Kohno T
    Gynecol Oncol; 2019 Dec; 155(3):489-498. PubMed ID: 31604667
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing.
    Kim SI; Lee JW; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS; Seo JS
    Gynecol Oncol; 2018 Feb; 148(2):375-382. PubMed ID: 29233531
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Demographic Clinical and Prognostic Factors of Primary Ovarian Adenocarcinomas of Serous and Clear Cell Histology-A Comparative Study.
    Schnack TH; Høgdall E; Nedergaard L; Høgdall C
    Int J Gynecol Cancer; 2016 Jan; 26(1):82-90. PubMed ID: 26569060
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genomic characterization of Chinese ovarian clear cell carcinoma identifies driver genes by whole exome sequencing.
    Yang Q; Zhang C; Ren Y; Yi H; Luo T; Xing F; Bai X; Cui L; Zhu L; Ouyang J; Jiang P; Fan W; Qiu J; Wang F; Xing X; Zhang Z; Zhang X; Zhang R
    Neoplasia; 2020 Sep; 22(9):399-430. PubMed ID: 32650224
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chromosome 20q13.2 ZNF217 locus amplification correlates with decreased E-cadherin expression in ovarian clear cell carcinoma with PI3K-Akt pathway alterations.
    Huang HN; Huang WC; Lin CH; Chiang YC; Huang HY; Kuo KT
    Hum Pathol; 2014 Nov; 45(11):2318-25. PubMed ID: 25281027
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of somatic genetic alterations in ovarian clear cell carcinoma with next generation sequencing.
    Shibuya Y; Tokunaga H; Saito S; Shimokawa K; Katsuoka F; Bin L; Kojima K; Nagasaki M; Yamamoto M; Yaegashi N; Yasuda J
    Genes Chromosomes Cancer; 2018 Feb; 57(2):51-60. PubMed ID: 29044863
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endometriosis does not confer improved prognosis in ovarian clear cell carcinoma: a retrospective study at a single institute.
    Zhao T; Shao Y; Liu Y; Wang X; Guan L; Lu Y
    J Ovarian Res; 2018 Jun; 11(1):53. PubMed ID: 29941051
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma.
    Kuo KT; Mao TL; Jones S; Veras E; Ayhan A; Wang TL; Glas R; Slamon D; Velculescu VE; Kuman RJ; Shih IeM
    Am J Pathol; 2009 May; 174(5):1597-601. PubMed ID: 19349352
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling.
    Chandler RL; Damrauer JS; Raab JR; Schisler JC; Wilkerson MD; Didion JP; Starmer J; Serber D; Yee D; Xiong J; Darr DB; Pardo-Manuel de Villena F; Kim WY; Magnuson T
    Nat Commun; 2015 Jan; 6():6118. PubMed ID: 25625625
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.
    Wiegand KC; Hennessy BT; Leung S; Wang Y; Ju Z; McGahren M; Kalloger SE; Finlayson S; Stemke-Hale K; Lu Y; Zhang F; Anglesio MS; Gilks B; Mills GB; Huntsman DG; Carey MS
    BMC Cancer; 2014 Feb; 14():120. PubMed ID: 24559118
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma.
    Huang HN; Lin MC; Huang WC; Chiang YC; Kuo KT
    Mod Pathol; 2014 Jul; 27(7):983-90. PubMed ID: 24336158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis.
    Ayhan A; Kuhn E; Wu RC; Ogawa H; Bahadirli-Talbott A; Mao TL; Sugimura H; Shih IM; Wang TL
    Mod Pathol; 2017 Feb; 30(2):297-303. PubMed ID: 27767100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genomic Sub-Classification of Ovarian Clear Cell Carcinoma Revealed by Distinct Mutational Signatures.
    Oliveira DVNP; Schnack TH; Poulsen TS; Christiansen AP; Høgdall CK; Høgdall EV
    Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680390
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of the number of cycles of platinum-based chemotherapy for early stage ovarian clear cell carcinoma on survival: a retrospective study.
    Gao Y
    BMC Womens Health; 2023 May; 23(1):262. PubMed ID: 37189098
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Kawahara N; Yamada Y; Kobayashi H
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070839
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.
    Rahman M; Nakayama K; Rahman MT; Nakayama N; Ishikawa M; Katagiri A; Iida K; Nakayama S; Otsuki Y; Shih IeM; Miyazaki K
    Hum Pathol; 2012 Dec; 43(12):2197-206. PubMed ID: 22705003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.